



Atty. Docket No. 1506-1053

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

WAHLGREN et al.

Confirmation No. 4801

Serial No. 09/508,967

GROUP 1645

Filed April 7, 2000

Examiner Lynette F. Smith

MALARIA POLYPEPTIDES

AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Responsive to the Official Action of October 16, 2002,
please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 31, replace the paragraph, beginning on line 13,
bridging pages 31 and 32, as follows:

--Two degenerate primers (DBL-1.1, 5'-GG(A/T) GC(A/T)
TG(TC) GC(A/T) CC(A/T) T(A/T)(T/C) (A/C) G-3' (SEQ ID NO: 2);
DBL-1.2, 5' -A(A/G)(A/G)T A(T/C)TG (T/A)GG (A/T)AC (A/G)TA
(A/G)TC-3' (SEQ ID NO: 3) which mapped to the conserved region of
all PfEMP1 DBL-1 were modified from the sequences of Su et al.
The amplification parameters were first optimised so that the
amplified products were visible with normal ethidium bromide (EB)
staining (Cobb, B. D. and J.M. Clarkson, 1994. A simple
procedure for optimising the polymerase chain reaction (PCR)
using modified Taguchi methods, Nucl. Acid. Res. 22, 3801-3805).

TECH CENTER 1600/2900

APR 09 2003

RECEIVED

E